Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,044 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.
Sayal K, Gounaris I, Basu B, Freeman S, Moyle P, Hosking K, Iddawela M, Jimenez-Linan M, Abraham J, Brenton J, Hatcher H, Earl H, Parkinson C. Sayal K, et al. Among authors: freeman s. Int J Gynecol Cancer. 2015 Jul;25(6):977-84. doi: 10.1097/IGC.0000000000000448. Int J Gynecol Cancer. 2015. PMID: 25962114 Free PMC article. Clinical Trial.
Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.
Parkinson CA, Gale D, Piskorz AM, Biggs H, Hodgkin C, Addley H, Freeman S, Moyle P, Sala E, Sayal K, Hosking K, Gounaris I, Jimenez-Linan M, Earl HM, Qian W, Rosenfeld N, Brenton JD. Parkinson CA, et al. Among authors: freeman s. PLoS Med. 2016 Dec 20;13(12):e1002198. doi: 10.1371/journal.pmed.1002198. eCollection 2016 Dec. PLoS Med. 2016. PMID: 27997533 Free PMC article.
Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.
Goranova T, Ennis D, Piskorz AM, Macintyre G, Lewsley LA, Stobo J, Wilson C, Kay D, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Freeman S, Moore L, Jimenez-Linan M, Paul J, Brenton JD, McNeish IA. Goranova T, et al. Among authors: freeman s. Br J Cancer. 2017 May 9;116(10):1294-1301. doi: 10.1038/bjc.2017.86. Epub 2017 Mar 30. Br J Cancer. 2017. PMID: 28359078 Free PMC article.
Diffusion-weighted imaging in gynaecological malignancy.
Addley H, Moyle P, Freeman S. Addley H, et al. Among authors: freeman s. Clin Radiol. 2017 Nov;72(11):981-990. doi: 10.1016/j.crad.2017.07.014. Epub 2017 Aug 23. Clin Radiol. 2017. PMID: 28842113 Review.
Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.
Goranova T, Ennis D, Piskorz AM, Macintyre G, Lewsley LA, Stobo J, Wilson C, Kay D, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Freeman S, Moore L, Jimenez-Linan M, Paul J, Brenton JD, McNeish IA; BriTROC investigators. Goranova T, et al. Among authors: freeman s. Br J Cancer. 2019 Apr;120(8):868. doi: 10.1038/s41416-019-0433-6. Br J Cancer. 2019. PMID: 30862952 Free PMC article.
Sodium MRI with 3D-cones as a measure of tumour cellularity in high grade serous ovarian cancer.
Deen SS, Riemer F, McLean MA, Gill AB, Kaggie JD, Grist JT, Crawford R, Latimer J, Baldwin P, Earl HM, Parkinson CA, Smith SA, Hodgkin C, Moore E, Jimenez-Linan M, Brodie CR, Addley HC, Freeman SJ, Moyle PL, Sala E, Graves MJ, Brenton JD, Gallagher FA. Deen SS, et al. Among authors: freeman sj. Eur J Radiol Open. 2019 Apr 19;6:156-162. doi: 10.1016/j.ejro.2019.04.001. eCollection 2019. Eur J Radiol Open. 2019. PMID: 31032385 Free PMC article.
Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer.
Deen SS, Priest AN, McLean MA, Gill AB, Brodie C, Crawford R, Latimer J, Baldwin P, Earl HM, Parkinson C, Smith S, Hodgkin C, Patterson I, Addley H, Freeman S, Moyle P, Jimenez-Linan M, Graves MJ, Sala E, Brenton JD, Gallagher FA. Deen SS, et al. Among authors: freeman s. Sci Rep. 2019 Jul 24;9(1):10742. doi: 10.1038/s41598-019-47195-4. Sci Rep. 2019. PMID: 31341212 Free PMC article.
Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker.
Winfield JM, Wakefield JC, Dolling D, Hall M, Freeman S, Brenton JD, Lutchman-Singh K, Pace E, Priest AN, Quest RA, Taylor NJ, Gabra H, McKnight L, Collins DJ, Banerjee S, Hall E, deSouza NM. Winfield JM, et al. Among authors: freeman s. Radiology. 2019 Nov;293(2):374-383. doi: 10.1148/radiol.2019190545. Epub 2019 Oct 1. Radiology. 2019. PMID: 31573402
Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis.
Winfield JM, Wakefield JC, Brenton JD, AbdulJabbar K, Savio A, Freeman S, Pace E, Lutchman-Singh K, Vroobel KM, Yuan Y, Banerjee S, Porta N, Ahmed Raza SE, deSouza NM. Winfield JM, et al. Among authors: freeman s. Br J Cancer. 2021 Mar;124(6):1130-1137. doi: 10.1038/s41416-020-01217-5. Epub 2021 Jan 4. Br J Cancer. 2021. PMID: 33398064 Free PMC article.
2,044 results